Atomwise operates in the pharmaceutical industry by using artificial intelligence (AI) to enhance drug discovery. The main product is an AI engine that employs machine learning and convolutional neural networks to analyze extensive chemical libraries. This technology allows Atomwise to identify new small molecule medicines more efficiently than traditional methods. The company primarily serves clients in healthcare and pharmaceuticals, aiming to streamline the drug discovery process. Atomwise's business model involves developing and co-developing drug candidates, which are then sold to pharmaceutical companies or healthcare providers. What sets Atomwise apart from competitors is its integration of AI and machine learning, which accelerates the creation of effective medicines while reducing costs and time. The ultimate goal of Atomwise is to improve patient outcomes by delivering better treatments more quickly.

Monsanto

Dolby Family Ventures

Baidu Ventures

DFJ Growth

Khosla Ventures

B Capital Group

Y Combinator

DCVC

Sanabil

AME Cloud Ventures

Tencent

Bill & Melinda Gates Foundation

Grand Challenges Canada

Sanofi

Mission and Market

Farzad (Zod) Nazem

OS Fund

David E. Weekly

Draper Associates

AI & Machine Learning

Biotechnology

Atomwise

SAN FRANCISCO--(BUSINESS WIRE)--Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter. The landmark study applied AtomNet to 318 targets through collaborations with over 250 academic labs across 30 countries, representing the largest and most comprehensive virtual HTS campaign reported to date. In a paper published in Nature Scientific Reports, AtomNet successfully identified structurally novel hits for 235 of 318 targets evaluated, representing a significant improvement in hit success rate over traditional HTS. AtomNet demonstrated consistently high hit rates across all target classes, which covered a wide breadth of protein classes relevant across major therapeutic areas, confirming the broad applicability of the AI platform. AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target. Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery

Atomwise Publishes Results From 318-Target Study Showcasing Atomnet Ai Platform’S Ability To Discover Structurally Novel Chemical Matter

Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer.

Atomwise Inc. hired Gavin Hirst as Chief Scientific Officer on Sep 14th 22'.

In April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma, a leading biopharmaceutical company in China, after successfully completing their first hit-discovery collaboration to identify hit compounds that are specific towards an intractable drug target.

Atomwise Inc. partnered with Hspharm on Apr 1st 20'.

An active A.I. driven drug development company since the beginning, Atomwise recently introduced A.I. based 'AtomNet PoseRanker (ANPR)' with improved performance.

The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies

Cerio joins Atomwise from Triplet Therapeutics, where he was general counsel.

Atomwise hires Cerio as general counsel

Jeffrey Cerio, Pharm.D., J.D. joins Atomwise from Triplet Therapeutics where he was General Counsel and Corporate Secretary.

J.D. leaves Triplet Therapeutics, Inc. as General Counsel and Corporate Secretary

San Francisco-based startup Atomwise, which uses artificial intelligence to drive drug discovery, has raised $175 million in venture capital funding.

Atomwise receives financing of $175M in venture capital funding

Atom­wise has hired Neely Mozaf­far­i­an as its chief med­ical of­fi­cer, CEO Abra­ham Heifets told End­points News in an ex­clu­sive in­ter­view on his com­pa­ny's fu­ture.

Ex­clu­sive: 'Faster is­n't bet­ter' - Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

SAN FRANCISCO--(BUSINESS WIRE)--Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery across a range of therapeutic areas. He was instrumental in the discovery and development of lorpucitinib and mivatonib, and is co-inventor of vaborbactam, which was approved by the U.S. Food and Drug Administration in combination with meropenem. Most recently, Dr. Hirst served as Interim CSO of Turning Point Therapeutics, which was acquired in August by Bristol Myers Squibb for $4.1 billion. “At Atomwise, we continue to reimagine how drug discovery should be done, now that our AI-enabled engine allows us to interrogate novel chemical space and gives us the potential to drug challenging targets,” said Abraham Heifets, Ph.D., Co-Founder and CEO of Atomwise. “Gavin brings deep expertise in structure- and fragment-based drug discovery, and a fantastic track record in driving those initial discoveries to become new medicines to help patients. We are thrilled that he is joining our team.”

Atomwise

AI-driven drug discovery platform

Atomwise

AI-driven drug discovery platform

About

Simplify's Take

What believers are saying

What critics are saying

What makes Atomwise unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

There are no jobs for Atomwise right now.